Galectin Therapeutics Inc. 2014 Form 10-K Summary
Business Context and Reporting Period
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic diseases and cancer. The filing covers the fiscal year ended December 31, 2014, including fourth-quarter results. The company had no commercial products or revenue and focused primarily on GR-MD-02, with GM-CT-01 in a substantially reduced development role.
- GR-MD-02 completed Phase 1 development in patients with NASH and advanced liver fibrosis. The company planned to begin Phase 2 trials in the first half of 2015.
- GR-MD-02 was also being evaluated in an investigator-sponsored Phase 1B melanoma immunotherapy study with ipilimumab.
- The prior GM-CT-01 melanoma trial in Belgium was placed on hold because of insufficient patient enrollment, not reported safety concerns.
Financial Performance and Position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | None | None | Pre-revenue |
| Research and development expense | $8.425 million | $5.688 million | +48% |
| General and administrative expense | $7.005 million | $6.416 million | +9% |
| Total operating expenses | $15.430 million | $12.104 million | +27% |
| Net loss | $15.788 million | $12.088 million | +31% loss |
| Net loss applicable to common stockholders | $16.960 million | $21.947 million | Improved, primarily due to the absence of the 2013 warrant modification charge |
| Basic and diluted loss per share | $0.78 loss | $1.30 loss | Improved |
| Net cash used in operations | $12.426 million | $7.484 million | +$4.942 million |
| Net cash from financing | $31.465 million | $8.609 million | +$22.856 million |
| Cash and cash equivalents at year-end | $29.128 million | $10.489 million | +$18.639 million |
| Total debt | None reported | None reported | No debt |
Fourth-quarter 2014 net loss was $3.731 million, or $3.968 million applicable to common stockholders, resulting in a basic and diluted loss of $0.17 per share. The filing does not provide revenue or operating margin because the company had no revenue.
- Research and development spending increased because of Phase 1 trial costs, preclinical work supporting Phase 2, and drug manufacturing costs.
- General and administrative expense included higher legal costs, including approximately $150,000 related to shareholder litigation, and higher insurance expense.
- Stock-based compensation expense was $4.070 million in 2014, compared with $3.789 million in 2013.
- Total assets were $29.677 million and stockholders’ equity was $21.195 million at December 31, 2014.
- Accumulated deficit was $118.925 million.
Material Changes Versus the Prior Comparable Period
- Operating cash burn rose substantially as clinical and preclinical activities expanded.
- The company raised approximately $29.337 million through at-the-market common-stock issuances and received $2.128 million from option and warrant exercises during 2014.
- Common shares outstanding increased to 22.277 million at December 31, 2014, from 18.387 million at December 31, 2013, creating dilution risk.
- The 2013 net loss included an $8.763 million non-cash warrant modification charge; no comparable charge occurred in 2014, reducing the loss attributable to common stockholders despite higher operating expenses.
- The company paid a $1.0 million separation obligation to former CEO David Platt in July 2014 after an arbitrator ruled in his favor.
- In January 2014, the company formed Galectin Sciences LLC with SBH Sciences to develop oral small-molecule galectin-3 inhibitors. The company’s ownership increased to 54.2% at year-end after funding additional expenses.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- Management expected to initiate a Phase 2 GR-MD-02 trial in the first half of 2015. The planned primary endpoint was hepatic venous pressure gradient, with liver collagen and non-invasive measures as secondary endpoints.
- Management stated that available cash, including approximately $4.127 million of net ATM proceeds raised in January and February 2015, was expected to fund planned operations through September 30, 2016. Additional capital would be required thereafter.
- The company remained dependent on equity financing and warned that failure to obtain additional funding could require significant operational reductions, cessation of operations, or bankruptcy protection.
- Clinical-stage risks include failure to demonstrate efficacy or safety, trial enrollment delays, regulatory rejection, manufacturing constraints, and uncertainty regarding the timing and cost of future trials.
- Pending securities class-action and shareholder derivative lawsuits alleged misleading public statements and fiduciary-duty violations. The company could not estimate potential losses, although it did not believe reasonably possible losses were material based on information then available.
- Series B preferred stock carried 12% dividends, redemption rights beginning in specified circumstances, voting and consent rights, and restrictions on debt, acquisitions, securities issuances and other corporate actions.
- Outstanding potentially dilutive instruments at year-end included approximately 5.471 million warrants, 3.333 million options and 2.527 million shares issuable upon preferred-stock conversion.
- The company relied on third-party manufacturers, clinical research organizations and research collaborators, and had no internal commercial manufacturing or sales infrastructure.
- McGladrey LLP issued unqualified opinions on the financial statements and the effectiveness of internal control over financial reporting.
Important Facts for Investors to Verify
- Whether GR-MD-02 Phase 2 trials were initiated as planned and whether clinical endpoints were met.
- Actual cash burn, financing activity and remaining liquidity relative to the stated September 30, 2016 funding horizon.
- Future equity issuance, warrant exercise and preferred-stock conversion activity and the resulting dilution.
- Developments and potential financial exposure from the securities class-action and derivative litigation.
- Regulatory feedback, trial enrollment, safety findings and manufacturing readiness for GR-MD-02.
- Whether the company generated any revenue or obtained product approval; the 2014 filing reports no revenue and no approved products.